Status:
COMPLETED
Head-to-head Comparison of Empagliflozin and Dapagliflozin
Lead Sponsor:
Chungbuk National University Hospital
Conditions:
Type2 Diabetes
Eligibility:
All Genders
18-80 years
Brief Summary
This open-labeled, prospective, observational, 3-year, clinical study was conducted to compare the effectiveness and safety between empagliflozin (25 mg once daily) and dapagliflozin (10 mg once daily...
Detailed Description
All participants included in this study were initially requested to initiate therapy with insulin, but they insisted on another form of OAD. When participants declined insulin injection and requested ...
Eligibility Criteria
Inclusion
- Inadequately controlled under triple OADs (metformin, glimepiride, dipeptidyl peptidase inhibitor) as evidenced by HbA1c 7.5-12%
Exclusion
- Type 1 diabetes
- Gestational diabetes
- Diabetes due to secondary causes
- Receiving anticancer treatment
- Receiving glucocorticoids or immune-suppressants
- have been treated with sodium-glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering this study
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03748810
Start Date
January 1 2016
End Date
June 30 2022
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National University Hospital
Cheonju, North Chungcheong, South Korea, 28644